The rule of three

There's something about Pyc. Even the market appears to have recognised a crossing over from just another biotech to a focused drug development company. So what might be happening that is driving a change in investor psychology?

The recent Investor Relation Presentation quotes from an article published in Neurotherapeutics in April 2019; "in the long run, oligonucleotides are likely to become a major class of therapeutics, on par with small molecules and biologics". Nucleic Acid Therapeutics for Neurological Diseases. Neurotherapeutics 16, 245–247 (2019). Watts, J.K., Brown, R.H. & Khvorova, A.

Number 1 - Pyc are in the vanguard of one of the fastest growing therapeutic classes on the planet.

During the last couple of decades Pyc has been wondering what to do with its platform and class of CPPs. Along the way it changed direction a number of times but in the process developed some handy tools and most recently adopted some key strategic partnerships. Nowadays, Pyc 'has a defensible competitive advantage' because its 'delivery technology ensures more drug reaches its target' [slide 3].

Number 2 - Solving the delivery problem is a game changer in RNA therapeutics.

Borrowing from the aforementioned article, we find another piece of the puzzle. The authors note that, "if a chemical modification is functional and nontoxic for one antisense oligonucleotide, it is an ideal starting point for the development of others". Pyc are operating in a therapeutic class which is conspicuous for its speed of development. How fast? Read the article and the reference to the group from Harvard Medical School who developed a custom drug for a single patient with Batten disease.

Number 3 - Time span for development of new targets is dramatically foreshortened.